NCT03096834: A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies
- State
- Completed
- Phase
- Phase 3
- People
- 246 taking part
- Started
- 20 Mar 2017
- Primary completion
- 18 Jan 2018
- Arms
- AMG334 140 mg DB, AMG334 140 mg DB cont on AMG334 140 mg, Placebo in DB to AMG334 140 mg
- Results
- Posted on the registry
- 20 Mar 2017: Trial started
- 30 Mar 2017: Trial registered
- 28 Jan 2021: Trial completed
- 18 Feb 2022: Trial results posted